The Novitas Team

Paul J. Schmitt

Managing Director

610-254-4286 pschmitt@novitascapital.com

 

(continued)

 

With clinical and pre-clinical operating companies in 7 countries, Chrysalis’ clients included over 250 biotech and pharmaceutical industry companies in 26 countries.

 

In April 1999, Chrysalis was merged with Phoenix International, Inc. (NASDAQ: PHXI).  Prior to forming Chrysalis, Mr. Schmitt joined DNX as the company’s first President and Chief Executive Officer in 1988.  While as CEO of DNX, Mr. Schmitt formed Nextran, a joint venture with Baxter Health Care focused on genetically engineered organ and blood substitute products.

 

Baxter funded the joint venture with an initial $20 Million investment and subsequently acquired Nextran in 1995. Mr. Schmitt served as President of Nextran until the sale to Baxter.

 

Prior to joining DNX, Mr. Schmitt was President of Biolectron, Inc., which developed therapeutic devices for treating a variety of debilitating orthopedic disorders.  He also has eight years experience with the BOC Health Care Group where he served as Vice President, General Manager of Ohmeda and as Corporate Manager of Strategic Planning and Corporate Group Finance Manager.

 

Mr. Schmitt currently serves on the Board of Trustees of the Wistar Institute and is Chairman of its Intellectual Property Committee. He serves on the Boards of Directors of 4 Novitas Capital portfolio companies: Amorcyte, Logical Therapeutics, Tetralogic Pharmaceuticals and GelMed. Mr. Schmitt received his BS in Finance at Lehigh University (’74), and his MBA from Rutgers University (’79).

 

Page: 1 2